Clinical Trial

Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)

Name: Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) — clinical trial record (NCT06753890)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study will evaluate the efficacy and safety of Changkang granules in the treatment of irritable bowel syndrome with predominant Diarrhea ( Liver qi affecting the spleen pattern)

Trial Details

NCT Number	NCT06753890
Lead Sponsor	Tasly Pharmaceutical Group Co., Ltd
Conditions	Diarrhea-predominant Irritable Boewl Syndrome
Enrollment	520 participants
Start Date	2024-12-30
Primary Completion	2026-11-11 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-12-31